SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Centocor ( CNTO ) -- Ignore unavailable to you. Want to Upgrade?

To: PawPr who wrote (495)1/7/1998 6:22:00 PM
From: FNS  Read Replies (1) | Respond to of 965
 
Bruce: <<IT'S A MOOT POINT UNTIL THE DRUG (AVAKINE ) IS APPROVED ANYWAY.>> You're right, but when the shareholders were led to believe
that a partner would be announced by year-end and it didn't happen, the shareholders got "impatient"! CNTO needs to complete the deal this QTR else the stock may dive again...any significant rallies might be based on soon to be announced partner news in addition to expected ReoPro earnings.

<<...SEVERAL COMPETING OFFERS>> Sounds like if this is/were true, then CNTO is in the driver's seat! Wonderful.

Any thoughts on when this drug will actually get approval?

Thanks for your insight.




To: PawPr who wrote (495)1/8/1998 12:48:00 PM
From: Giuseppe Scalamogna  Read Replies (1) | Respond to of 965
 
Bruce,

That is not what I have understood. CNTO had a company (unnamed) at the table and the deal was ready to be agreed upon when supposedly the co. in question made an extra demand and so CNTO decided to pull out of the deal. The company has been very sketchy on this and have been with the analysts as well.

GS


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News